Radial-Artery Grafts Better Than Saphenous-Vein Grafts in CABG

Share this content:
Radial-Artery Grafts Better Than Saphenous-Vein Grafts in CABG
Radial-Artery Grafts Better Than Saphenous-Vein Grafts in CABG

WEDNESDAY, June 6, 2018 (HealthDay News) -- Compared to saphenous-vein grafts, radial-artery grafts are associated with a lower rate of adverse cardiac events at five-year follow-up in coronary-artery bypass grafting (CABG) patients, according to research published in the May 31 issue of the New England Journal of Medicine.

Mario Gaudino, M.D., from Weill Cornell Medicine in New York City, and colleagues performed a patient-level combined analysis of six randomized, controlled trials to compare radial-artery grafts (534 patients) and saphenous-vein grafts (502 patients) for CABG.

The researchers found that over a mean 60 months of follow-up, the incidence of adverse cardiac events was significantly lower with radial-artery grafts versus with saphenous-vein grafts (hazard ratio [HR], 0.67; 95 percent confidence interval [CI], 0.49 to 0.90; P = 0.01). The use of radial-artery grafts was also associated with a significantly lower risk of occlusion (HR, 0.44; 95 percent CI, 0.28 to 0.70; P < 0.001) at follow-up angiography. There was a nominally lower incidence of myocardial infarction (HR, 0.72; 95 percent CI, 0.53 to 0.99; P = 0.04) and a lower incidence of repeat revascularization (HR, 0.50; 95 percent CI, 0.40 to 0.63; P < 0.001) but not a lower incidence of all-cause death (HR, 0.90; 95 percent CI, 0.59 to 1.41; P = 0.68) with the use of radial-artery grafts versus saphenous-vein grafts.

"As compared with the use of saphenous-vein grafts, the use of radial-artery grafts for CABG resulted in a lower rate of adverse cardiac events and a higher rate of patency at five years of follow-up," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »